The clinical trial of rG-CSF for hepatitis B virus-associated acute-on-chronic liver failure
XU Xiang
LIU Xiao-yan
CHEN Jing
XIAO Long
TONG Jing-jing
Guan Chong-dan
YAN Li-long
SU Hai-bin
HU Jin-hua
Abstract：Objective To evaluate the safety and efficiacy of rG-CSF on patients with hepatitis B virus-associated acute-on-chronic liver failure (ACLF). Methods A total of 99 cases of ACLF were randomly divided into 2 groups, 49 cases in the experimental group and 50 cases in the control group. The control group was given internal comprehensive treatment while the experimental group on the basis of the internal comprehensive treatment received rG-CSF 300 g, once per day, subcutaneous injection, six injections in total, and then reduced to once every other day, a total of 6 times, 12 injections in total. Results Survival analysis showed that the survival rates of the experimental group in January and March were 91.3% and 72.9% respectively, which were higher than those in the control group of 63.7% and 50% (P < 0.05). There were no serious adverse effects during the treatment period. Conclusions rG-CSF can significantly improve the survival rate of patients with HBV-ACLF with higher security.
Keywords：granulocyte-colony stimulating factorHBVacute-on-chronic liver failureclinical trial
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 279-283 )